Abstract:
Impact of tumour volume on the potential efficacy of therapeutic vaccines
J.L. Gulley, MD PhD*, R.A. Madan, MD*, J. Schlom, PhD*
*Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.
With the recent approval by the U.S. Food and Drug Administration of the first therapeutic vaccine for cancer, the long-awaited goal of harnessing a patient’s immune system to attack cancer through this modality is finally realized. However,
